Grace Therapeutics Inc

GRCE30 Nov 2024
Healthcare
$3.34
0.00 (-0.30%)
Lowest Today
$3.32
Highest Today
$3.44
Today’s Open
$3.34
Prev. Close
$3.37
52 Week High
$3.6
52 Week Low
$1.98
To Invest in Grace Therapeutics Inc

Grace Therapeutics Inc

Healthcare
GRCE30 Nov 2024
0.00 (-0.30%)
1M
3M
6M
1Y
5Y
Low
$3.32
Day’s Range
High
$3.44
3.32
52 Week Low
$1.98
52-Week Range
52 Week High
$3.6
1.98
1 Day
-
1 Week
-
1 month return
+4.37%
3 month return
-1.18%
6 month return
-1.18%
1 Year return
-
3 Years return
-
5 Years return
-
10 Years return
-

Market Status

Fundamentals
Market Cap
0
PB Ratio
0
PE Ratio
0
Enterprise Value
0
Total Assets
73.3 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal betamethasone spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. The company was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Organisation
Grace Therapeutics Inc
Employees
0
Industry
Biotechnology
CEO
Mr. Prashant  Kohli
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step

Click here to see your activities